PROPOFOL
Sleep Apnea Syndrome
Icahn School of Medicine at Mount SinaiSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Sleep Apnea Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trazodone Chang Gung Memorial Hospital | Phase 4 | BB |
VALSARTAN University Hospital, Grenoble | Phase 4 | BB |
AMLODIPINE University Hospital, Grenoble | Phase 4 | BB |
Mazdutide Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | B |
NEPENTHE American University of Beirut Medical Center | Phase 2/3 | B |
View all 18 →
Same molecule, other indications
PROPOFOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →